Dyadic International, Inc.

We are a global biotechnology company with patented and proprietary technologies that are used to discover, develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. Dyadic leverages the value of its technologies through licensing arrangements and other collaborations with third parties who receive the benefits of producing and using the proteins these technologies help produce.

Company details

140 Intracoastal Pointe Drive, Suite 404 , Jupiter , Florida 33477-5094 USA

More Office Locations Locations Served

Business Type:
Industry Type:
Market Focus:
Globally (various continents)

This company also provides solutions for other industrial applications.
Please, visit the following links for more info:

Dyadic International, Inc. (OTC Pink: DYAI) is a global biotechnology company located in Jupiter, Florida with its main research and development operations located in The Netherlands.

Dyadic is focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, biochemical, industrial enzyme and biopharmaceutical industries.

State-of-the-art platform

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins.

Dyadic’s technologies overcome the inadequacy of existing gene discovery and product development techniques which have limited capabilities to efficiently access the full spectrum of earth’s biodiversity. Dyadic’s unique technology increases the likelihood that each time a useful gene is discovered, it can also be expressed and then mass-produced.

Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Serving diverse industries

Dyadic currently sells more than 55 liquid and dry enzyme products to more than 150 industrial customers in approximately 50 countries for a broad range of industries including biofuels, bio-based chemicals, biopharmaceuticals, animal health and nutrition, pulp & paper, textiles, food and beverage, and nutraceuticals.


Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems.


Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts.

Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, chemical and biopharmaceutical industries that have in-house genomic capabilities. Dyadic will also collaborate with companies whose genomic capabilities are limited, discovering and expressing biological materials for these strategic partners.

In addition, Dyadic, using these proprietary systems, will continue to commercialize enzymes for use in targeted markets, including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries.

Dyadic expects to generate revenue from its product sales, revenue generated from research and development services and funding as well as revenue generated from licensing and other strategic collaborations in the form of milestone and royalty payments.